
Amgen has announced it will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of …

Bristol-Myers Squibb has signed a collaboration agreement with the US biotech firm Five Prime Therapeutics, for a Colony Stimulating Factor …

Bristol-Myers Squibb has announced a new research and development deal with Five Prime Therapeutics aimed at discovering potentially new cancer …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

